Minimum Order Quantities Vary By Product
đźšš Save BIG on Truckload orders!
Let me tell you about a pharmaceutical quality assurance manager who prevented a $45 million regulatory disaster by asking the right questions during supplier audit.
Their pharmaceutical company was qualifying new packaging supplier for materials including specialized liners and containment solutions. The procurement team had selected supplier based on competitive pricing (14% savings versus current supplier) and delivery commitments. Basic qualification completed. Facility tour scheduled. The procurement team planned standard manufacturing capability assessment.
The QA manager insisted on comprehensive pharmaceutical-specific questioning during audit. The procurement team resisted: “We’ve already verified they have ISO certification and pharmaceutical customers. Extended questioning wastes time and risks supplier relationships.”
The QA manager prevailed: “Pharmaceutical suppliers require specific verification beyond general manufacturing. I need to ask targeted questions uncovering pharmaceutical capability—or lack thereof. Twenty questions could save us millions in regulatory disasters.”
During the facility audit, the QA manager’s pharmaceutical-specific questions revealed shocking realities:
Question: “Do you manufacture non-pharmaceutical packaging in this facility?” Supplier: “Yes, we also produce industrial chemical packaging.”
Question: “How do you segregate pharmaceutical from chemical packaging manufacturing?” Supplier: “We run pharmaceutical materials on Mondays and Wednesdays. Chemical packaging runs Tuesdays and Thursdays. Same equipment with cleaning between.”
Question: “What’s your cleaning validation demonstrating no chemical cross-contamination?” Supplier: “We don’t have cleaning validation. We clean thoroughly between products. That’s always been adequate.”
The QA manager immediately identified catastrophic pharmaceutical compliance failure: Shared equipment between pharmaceutical and chemical packaging without cleaning validation. No demonstration that chemical residues eliminated. FDA would cite this as adulteration risk. Using this supplier would create regulatory disaster.
Additional questions revealed more problems: No pharmaceutical segregation in warehouse. Limited pharmaceutical documentation capability. Inadequate change control. No pharmaceutical-specific quality systems.
The QA manager stopped qualification immediately. Procurement protested: “But they have pharmaceutical customers! They claimed pharmaceutical capability!” QA manager’s response: “They have pharmaceutical customers with inadequate auditing. Our questions revealed what superficial audits missed. Using this supplier would have created $45M+ regulatory disaster when FDA audited our supply chain.”
They continued supplier search. Found properly qualified pharmaceutical supplier (Custom Packaging Products with pharmaceutical-grade segregation). Higher price but proper pharmaceutical capability verified through comprehensive QA questioning.
Here’s what pharmaceutical quality assurance needs to understand: 25 specific pharmaceutical questions during supplier audit distinguish genuine pharmaceutical capability from superficial claims—preventing multi-million-dollar regulatory disasters.
So when someone asks “what questions should QA ask a pharma packaging supplier,” they’re really asking: what 25 targeted questions verify genuine pharmaceutical capability versus dangerous claims?
Category 1: Pharmaceutical Segregation Questions (CRITICAL)
These questions identify catastrophic pharmaceutical compliance failures:
Question 1: “Do you manufacture non-pharmaceutical packaging in this facility?”
Why This Matters: Shared facilities between pharmaceutical and non-pharmaceutical (especially chemical, pesticide, hazardous materials) create cross-contamination risks. FDA considers this adulteration risk requiring strict controls.
Red Flag Answers: “Yes, we manufacture chemical packaging on same equipment.” “We produce industrial packaging but keep them separate.” (HOW separate?) “Most of our business is industrial with some pharmaceutical.” (Higher contamination risk from primary industrial focus.)
Acceptable Answers: “This is dedicated pharmaceutical packaging facility—no other use.” “We have separate pharmaceutical-only production lines never used for non-pharmaceutical.” “We manufacture food packaging (lower risk) with validated cleaning between.” (Still requires verification but less risky than chemical.)
Question 2: “How do you prevent cross-contamination between pharmaceutical and non-pharmaceutical packaging?”
Why This Matters: “Keeping them separate” is vague and inadequate. Need specific systems preventing contamination.
Red Flag Answers: “We clean between products.” (No validation mentioned.) “Different days of the week.” (Shared equipment without validation.) “We’re very careful.” (Not a system.) “That’s never been a problem.” (Lack of understanding regulatory requirements.)
Acceptable Answers: “Dedicated pharmaceutical equipment never exposed to non-pharmaceutical.” “Time-based segregation with validated cleaning removing all residues.” “Physical barriers and separate facilities.” “Validated changeover procedures with verification testing.”
Question 3: “Can you show me your cleaning validation for pharmaceutical/non-pharmaceutical changeover?”
Why This Matters: Cleaning validation PROVES adequate residue removal. Without validation, contamination risk uncontrolled.
Red Flag Answers: “We don’t have formal cleaning validation.” (CATASTROPHIC—disqualify immediately.) “We test periodically.” (Not validation—inadequate.) “Our cleaning is very thorough.” (Not validated—inadequate.) “That’s never been required by other customers.” (Those customers have inadequate programs.)
Acceptable Answers: “Here’s our cleaning validation protocol and reports showing residue limits and detection.” “We have validated limits for residues demonstrating no cross-contamination.” “Cleaning validation updated annually with revalidation.” (Shows complete validation with documentation.)
Call or Text us at 832.400.1394 for a Quote!
Question 4: “Where do you store pharmaceutical packaging materials? How do you prevent commingling with non-pharmaceutical materials?”
Why This Matters: Warehouse segregation prevents mix-ups between pharmaceutical and non-pharmaceutical materials.
Red Flag Answers: “Same warehouse, different sections.” (Risk of mix-up.) “We label them carefully.” (Labels can fail—need physical segregation.) “Pharmaceutical materials marked with special labels.” (Marking alone inadequate.)
Acceptable Answers: “Dedicated pharmaceutical warehouse—no non-pharmaceutical materials stored here.” “Separate pharmaceutical area with controlled access and physical barriers.” “All pharmaceutical materials in dedicated facility with no commingling possible.”
Category 2: Material Compliance Questions
Questions verifying pharmaceutical-grade materials:
Question 5: “Are your materials manufactured from virgin resins or do they contain recycled content?”
Why This Matters: Pharmaceutical materials typically require virgin resins. Recycled content creates contamination risks and regulatory concerns.
Red Flag Answers: “We use recycled content for cost savings.” (DISQUALIFY for pharmaceutical.) “Some recycled, some virgin.” (Contamination risk.) “We can use either based on customer preference.” (Lack of pharmaceutical understanding.)
Acceptable Answers: “100% virgin resins for ALL pharmaceutical materials—we never use recycled content for pharmaceutical.” “Virgin material specifications with certificates from resin suppliers.” “Our pharmaceutical materials exclusively use virgin FDA-compliant resins.”
Question 6: “What documentation proves your materials meet FDA requirements for pharmaceutical use?”
Why This Matters: FDA compliance must be documented, not claimed.
Red Flag Answers: “Our materials are pharmaceutical-grade.” (Claim without proof.) “We’ve never had FDA problems.” (Not proof of compliance.) “Our materials are clean.” (Not the standard.)
Acceptable Answers: “FDA compliance letters from resin suppliers for 21 CFR compliance.” “Complete documentation package including FDA compliance, extractables data, compositional analysis.” “Here’s our FDA regulatory compliance file for these materials.”
Question 7: “Do you provide extractables and leachables data for materials?”
Why This Matters: Direct product contact materials require extractables/leachables assessment.
Red Flag Answers: “We don’t have that data.” (Inadequate for critical applications.) “Never been requested.” (Limited pharmaceutical experience.) “Materials are inert.” (Not demonstrated—claim insufficient.)
Acceptable Answers: “Yes, here’s our extractables study protocol and results.” “We provide complete E&L data package with risk assessment.” “E&L testing available for critical applications—here’s our standard study.”
Category 3: Quality System Questions
Questions verifying pharmaceutical quality systems:
Question 8: “Do you have ISO 15378 certification for pharmaceutical packaging?”
Why This Matters: ISO 15378 is THE pharmaceutical packaging certification. Absence suggests inadequate pharmaceutical focus.
Red Flag Answers: “We have ISO 9001.” (Not pharmaceutical-specific—inadequate.) “We’re working toward ISO 15378.” (Not currently certified.) “We have pharmaceutical customers without ISO 15378.” (Those customers have inadequate programs.)
Acceptable Answers: “Yes, here’s our current ISO 15378 certificate with scope covering your materials.” “ISO 15378 certified facility with annual surveillance.” “Here’s our certification body information for verification.”
Question 9: “How do you demonstrate your manufacturing processes are validated and capable?”
Why This Matters: Process validation is cGMP requirement. Unvalidated processes create quality risks.
Red Flag Answers: “Our processes are proven through years of experience.” (Experience ≠validation.) “We monitor processes continuously.” (Monitoring ≠validation.) “Never had validation requirement.” (Limited pharmaceutical understanding.)
Acceptable Answers: “Here’s our process validation protocol and qualification studies (IQ/OQ/PQ).” “All critical processes validated with ongoing performance monitoring.” “Process validation per pharmaceutical requirements with revalidation schedule.”
Question 10: “What’s your lot traceability capability—how quickly can you trace materials forward and backward?”
Why This Matters: Rapid traceability essential for recalls and investigations. Slow traceability suggests poor systems.
Red Flag Answers: “We can eventually figure it out.” (Inadequate—too slow.) “It takes us 1-2 weeks to trace.” (Far too slow—suggests manual paper systems.) “We’ve never needed to trace materials.” (Unprepared for pharmaceutical requirements.)
Acceptable Answers: “24-hour complete forward and backward traceability.” “We can trace materials within 4-8 hours using our electronic systems.” “Here’s our mock recall exercise demonstrating 24-hour traceability.”
Question 11: “How do you control changes to materials, processes, or suppliers?”
Why This Matters: Inadequate change control creates uncontrolled risks. Changes without customer approval violate pharmaceutical requirements.
Red Flag Answers: “We notify customers of major changes.” (What defines “major”—too vague.) “We implement improvements as needed.” (Changes without notification/approval.) “Change control hasn’t been required.” (Inadequate pharmaceutical understanding.)
Acceptable Answers: “Formal change control requiring customer notification and approval BEFORE implementation.” “Here’s our change control procedure showing customer notification requirements.” “All changes undergo impact assessment and require customer approval before implementation.”
Category 4: Documentation Questions
Questions verifying documentation capabilities:
Question 12: “What documentation do you provide with each shipment?”
Why This Matters: Inadequate lot documentation prevents pharmaceutical material release.
Red Flag Answers: “We provide basic certificate of analysis.” (Basic ≠pharmaceutical-grade.) “Packing list and COA.” (Insufficient detail for pharmaceutical.) “Standard industrial documentation.” (Not pharmaceutical-adequate.)
Acceptable Answers: “Complete pharmaceutical documentation package: detailed lot-specific COA, certificate of conformance, raw material traceability, cGMP compliance statement.” “Here’s our standard pharmaceutical documentation package showing all elements.” “Pharmaceutical-grade COA with complete test results and traceability.”
Question 13: “Can you provide validation support documentation for new materials?”
Why This Matters: New material validation requires extensive documentation. Limited documentation capability prevents material validation.
Red Flag Answers: “We can provide COA.” (Insufficient for validation.) “What specific documentation do you need?” (Should already have standard package.) “We don’t typically provide validation documentation.” (Limited pharmaceutical experience.)
Acceptable Answers: “Standard validation support package includes: specifications, composition, extractables data, stability data, process description, regulatory compliance.” “Here’s our validation documentation package we provide for new materials.” “Complete validation support with all necessary documentation.”
Category 5: Capacity And Service Questions
Questions verifying sustainable supply capability:
Question 14: “What percentage of your business is pharmaceutical packaging?”
Why This Matters: Low pharmaceutical percentage suggests limited pharmaceutical focus and expertise.
Red Flag Answers: “5-10% pharmaceutical, mostly industrial.” (Limited focus on pharmaceutical requirements.) “We’re expanding pharmaceutical business.” (Inexperienced in pharmaceutical.) “Small but growing pharmaceutical presence.” (Limited pharmaceutical expertise.)
Acceptable Answers: “75%+ of our business is pharmaceutical packaging.” “Dedicated pharmaceutical packaging facility—100% pharmaceutical focus.” “Significant pharmaceutical business with Fortune 500 pharmaceutical customers.”
Question 15: “What’s your capacity utilization and ability to handle volume increases?”
Why This Matters: High utilization limits flexibility. Insufficient capacity creates supply problems.
Red Flag Answers: “We’re running at 95% capacity.” (No flexibility for growth.) “We’ll add capacity if needed.” (Reactive, not proactive.) “Capacity is tight but manageable.” (Red flag for supply problems.)
Acceptable Answers: “Currently 70-75% utilized with capacity for 25-30% growth.” “We maintain reserve capacity for customer growth.” “Adequate capacity with expansion plans for future growth.”
Additional Critical Questions:
Question 16: “What’s your regulatory inspection history? Any warning letters, 483s, or consent decrees?” (Must disclose—verify through FDA database.)
Question 17: “How do you handle customer complaints and investigations?” (Formal system required.)
Question 18: “What are your lead times and on-time delivery performance?” (Realistic expectations.)
Question 19: “Do you have business continuity plans for supply disruption?” (Risk mitigation.)
Question 20: “What technical support do you provide for material questions?” (Ongoing support capability.)
Question 21: “Can you provide references from pharmaceutical customers?” (Verify claims through references.)
Question 22: “What continuous improvement initiatives are you implementing?” (Quality culture.)
Question 23: “How do you qualify and control your raw material suppliers?” (Supply chain control.)
Question 24: “What testing capabilities do you have in-house versus external labs?” (Testing capacity.)
Question 25: “How do you ensure employee training on pharmaceutical requirements?” (Knowledge maintenance.)
What Comprehensive Pharmaceutical Supplier QA Questioning Includes
âś“ Segregation questions (preventing contamination disasters) âś“ Material compliance questions (verifying pharmaceutical-grade materials) âś“ Quality system questions (confirming pharmaceutical systems) âś“ Documentation questions (ensuring adequate documentation) âś“ Capacity/service questions (sustainable supply capability) âś“ Regulatory history questions (identifying risks) âś“ Technical support questions (ongoing capability)
Twenty-five targeted questions distinguish genuine pharmaceutical capability from dangerous superficial claims.
Stop Accepting Supplier Claims Without Verification
Your pharmaceutical quality assurance cannot afford accepting supplier “pharmaceutical capability” claims without comprehensive questioning—risking $45M+ regulatory disasters from inadequate suppliers.
Custom Packaging Products welcomes comprehensive QA questioning—ISO 15378 consideration, pharmaceutical-grade segregation, validated systems, complete documentation capability, 50+ years pharmaceutical experience.
Partner with the QA-interrogation-ready pharmaceutical packaging specialist since 1973.